ClinicalTrials.gg
CompletedNCT00909779Updated Nov 11, 2013Results posted

Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects

A Phase 3 interventional study of Arformoterol and Placebo in Chronic Obstructive Pulmonary Disease, sponsored by Sumitomo Pharma America, Inc.. Completed at 73 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2013-11-11.

Sponsored by Sumitomo Pharma America, Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
841
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 3 under way, 1 of them phase 3. formoterol · Pulmonary Disease, Chronic Obstructive.

Enrollment
21st of 89
841 · median 120
Started
2009
with 1 other
Phase 3
40 of 89
1 open now
Registered
26th of 89
by date
Lead sponsor
3 of 89
Sumitomo Pharma America, Inc.

Among the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive, this one is the 21st largest by enrollment, is one of 2 that started in 2009, is one of 40 in phase 3, and was the 26th registered.

Pulmonary Disease, Chronic Obstructive

5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

3 of the 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About formoterol

formoterol: first FDA approval 2001 (FORADIL), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 561 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies testing formoterol in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

This is a multi-center study to evaluate the long-term safety of arformoterol 15 mcg twice daily (BID) in the treatment of subjects with moderate-to-severe COPD. Study participation will consist of a total of 6 visits over approximately 1 year.

Read the detailed description

This is a multi-center, double-blind, randomized, placebo-controlled, parallel-group, outpatient, safety study to evaluate the long-term safety of arformoterol 15 mcg twice daily (BID) in the treatment of subjects with moderate-to-severe COPD. The administration of arformoterol in subjects with moderate to severe COPD will not result in a meaningfully greater incidence of respiratory death and COPD exacerbation -related hospitalizations compared to placebo (nebulized saline and non-long-acting beta2-agonist [LABA] COPD standard of care treatments). This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • Chronic obstructive pulmonary disease (COPD)
  • respiratory
  • long-acting beta agonist (LABA)
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must give written , including privacy authorization as well as adherence to concomitant medication withholding periods, prior to participation.
  • Females considered not of must be surgically sterile (total hysterectomy, bilateral salpingo oophorectomy, or tubal ligation) or , which is defined as a complete cessation of menstruation for at least 1 year.
  • Male and female subjects must be at least 40 years old at the time of consent.
  • Subjects must have a pre-established, documented primary clinical diagnosis of non-asthmatic or are referred for diagnosis of non-asthmatic COPD.
  • Subjects must have a baseline of ≤50% predicted volume at Visits 1 and 2 (pre-dose).
  • Subjects must have a FEV1 >0.50 L at either Visit 1 or 2 (pre-dose).
  • Subject's respiratory status must be clinically stable.
  • Subjects must have a FEV1/forced vital capacity (FVC) ratio of ≤70% at either Visit 1 or 2 (pre-dose).
  • Subjects must have had at least 1 COPD exacerbation within the last year (defined as initiation or an increase in the dose of oral or antibiotics for the treatment of COPD).
  • Subjects must have a ≥15 pack-year smoking history and a baseline breathlessness severity grade of ≥2 (Modified Medical Research Council [MMRC] Dyspnea Scale Score) at Visit 2.
  • Female subjects ≤65 years of age must have a negative serum pregnancy test conducted at Visit 1 prior to randomization. Females of childbearing potential must be using an acceptable method of .
  • Subjects' overall health must be sufficiently stable to complete the study requirements based on the screening physical examination (defined as the absence of any abnormalities), medical history, 12-lead , and clinical laboratory values (hematology, serum chemistry and urinalysis), and vital signs (heart rate, respiratory rate, and blood pressure) that have been conducted within 30 days of Visit 2 (randomization). If any of the hematology, chemistry, or urinalysis results are not within the laboratory's reference range, then the subject can be included only if the investigator judges the deviations to be not clinically significant.
  • Subjects must have a minimum blood pressure of 105/60 mmHg and a minimum resting pulse of 50 bpm at Screening Visit 1. Subjects who do not meet these criteria at Screening Visit 1 must meet the criteria on the first day of dosing (Day 1) in order to be eligible for the study. Subjects with a medical condition which causes low blood pressure or low heart rate, but, in the opinion of the Principal Investigator or designee the medical condition could resolve, may be rescreened when the condition is resolved.
  • Subjects must be willing and able to complete all study questionnaires and logs reliably.
  • Subjects must be willing and able to comply with study procedures and visit schedule.
  • Subjects must have sufficient understanding of English to complete all questionnaires and logs.

Exclusion criteria

Exclusion Criteria:

  • Female subjects who are pregnant or lactating.
  • Subjects with a history of asthma, with the exception of asthma diagnosed in childhood.
  • Subjects with a blood eosinophil count >5% of total white blood cell count.
  • Subjects with a febrile illness within 3 days before Screening.
  • Subjects with a malignant neoplasm other than non melanomatous basal cell skin cancer. Subjects with a history of who have been cancer free for 5 years or more may be enrolled.
  • Subjects who are currently using disallowed medications or will be unable to complete the medication . Subjects taking a prohibited concurrent medication which requires a washout of >30 days may be rescreened when the washout of the prohibited concurrent medication has been met.
  • Subjects with life threatening/unstable respiratory status, including upper or lower respiratory tract infection, within the previous 30 days prior to screening.
  • Subjects who have had a change in dose or type of any medications for within 2 weeks prior to the screening visit. Subjects not on a stable dose of COPD medications may be rescreened after being on a stable dose for at least 14 days
  • Subjects with a chest x ray taken ≤3 months prior to screening that suggests a diagnosis other than COPD (eg, diagnostic of pneumonia, other infection, atelectasis, or pneumothorax or other active/ongoing pulmonary conditions). If there is no chest x ray taken ≤3 months prior to screening, or if recent results are unavailable for review, a chest x ray must be performed prior to visit 2. Subjects with a medical condition that caused the abnormal finding, but, in the opinion of the Principal Investigator or designee the medical condition could resolve, may be rescreened when the condition is resolved
  • Subjects with a positive urine drug test during screening.
  • Subjects with a known history of alcohol abuse may be enrolled in the study if the subject's current alcohol use does not exceed more than 3 alcoholic beverages per day.
  • Subjects whose schedule or travel prevents the completion of all required visits.
  • Subjects who are scheduled for inpatient hospitalization or elective surgery (inpatient or outpatient) during the trial. Subjects may be rescreened when the condition is resolved.
  • Subjects have participated in an drug study and/or any COPD interventional trial within 30 days prior to screening or who are currently participating in another investigational drug study or COPD interventional trial.
  • Subjects with a history of allergic reaction to the study medication or any components of the study medications.
  • Subjects who are study site staff members or relatives of study site staff members directly involved in this study.
  • Subjects with cardiac, (Functional Class III and IV; Objective Class C and D by [NYHA] Functional Classification),hepatic, renal, gastrointestinal, endocrine, metabolic, neurologic, or psychiatric disorder that may interfere with successful completion of this protocol.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
841 participants (actual)

Study arms

  • Experimental
    Arformoterol 15 mcg twice daily

    Arformoterol 15 mcg twice daily by nebulization. All subjects will be dispensed albuterol HFA metered-dose inhaler (MDI) to be used as needed as rescue medication for bronchospasm and acute treatment of COPD symptoms.

    Drug: Arformoterol

  • Placebo comparator
    Placebo twice daily

    Placebo twice daily by nebulization. All subjects will be dispensed albuterol HFA metered-dose inhaler (MDI) to be used as needed as rescue medication for bronchospasm and acute treatment of COPD symptoms.

    Drug: Placebo

Interventions

  • Arformoterol Tartrate Inhalation Solution 15 mcg twice daily (BID) for a duration of one year

    Also known as: Brovana

  • DrugPlacebo

    Placebo inhalation solution, twice daily (BID) for a duration of one year.

06

What researchers measure

Primary outcomes

  1. Time From Randomization to Respiratory Death or First COPD Exacerbation Related Hospitalization (Whichever Occurs First).

    COPD exacerbation: an increase in COPD symptoms that necessitated any change in baseline medication (bronchodilators,anti-inflammatory agents, antibiotics, supplemental oxygen therapy, etc.).Hospitalization: any inpatient admission or any emergency department visit \> 24 hours in duration. Hospice was considered hospitalization.COPD exacerbation related hospitalization: hospitalization that was due to 1) COPD exacerbation or 2) a COPD exacerbation preceded, or occurred concomitantly with the onset of, the event for which the subject was hospitalized.Respiratory-related death: For each death the Primary Investigator designated a 'probable cause', which was the primary condition that precipitated the terminal events that were the immediate cause of death. If a probable cause could not be ascertained, the cause of death was considered 'UNKNOWN'. Cause other than 'UNKNOWN' was categorized as either respiratory or non-respiratory. Deaths of 'UNKNOWN' cause were counted as primary events.

    Time frame: 0-12 months

Secondary outcomes

  1. The Incidence of Protocol Defined COPD Exacerbations.

    A protocol-defined exacerbation of COPD was defined as an increase in respiratory symptoms (classically, increased shortness of breath, increased sputum production, and/or increased sputum purulence) that necessitates any change in baseline medication other than bronchodilators (e.g., anti-inflammatory agents, antibiotics, supplemental oxygen therapy, etc) or causes the subject to require additional medical attention (i.e., emergency room visit or hospitalization).

    Time frame: 0-12 months

  2. The Incidence of All Cause Mortality

    Survival status at the end of the study will be determined for each subject. The proportion of subjects dead and the annual event rate will be summarized by treatment.

    Time frame: 0-12 months

  3. The Incidence of Treatment Emergent AEs

    TEAEs were defined as: 1) adverse events that occurred on or after the date of first dose of study medication, 2) adverse events with a missing start date and a stop date on or after the date of first does of study medication, or 3) adverse events with both a missing start and stop date. The frequency and percentage of subjects with TEAEs were summarized. At each level of summarization, a subject was counted only once for each AE he/she experienced within that level. The percentage of subjects having had at least 1 AE at each level was calculated.

    Time frame: 0-12 months

  4. SGRQ: Mean Change From Baseline in Total Score

    The SGRQ assessed health status and consisted of 3 component scores (Symptoms, Activity, and Impacts) as well as a total score. Items were scored in accordance with the developer's guidelines. Scores were expressed as a percentage of overall impairment, where 100 represented worst possible health status and 0 indicated best possible health status. The SGRQ was assessed pre-dose at baseline, months 3, 6 and 12 or the end of study (EOS). Visit 2 was defined as baseline. A change from baseline in the Total Score of ≥ 4 units is considered the minimal clinically important difference (MCID) for SGRQ.

    Time frame: Baseline and on treatment at months 3, 6 and 12 (or early termination)

  5. FEV1: Mean Change From Baseline

    FEV1 was measured at Visit 1 (screening), pre- and post-albuterol administration for reversibility testing, pre-dose at baseline, months 3, 6, 9 and 12/EOS. The best FEV1 from at least 3 acceptable maneuvers was recorded. Study baseline was defined as the Visit 2 pre-dose value. If the Visit 2 pre-dose value was missing, the last FEV1 value obtained prior to first treatment was used for baseline.

    Time frame: Baseline and on treatments at months 3, 6, 9 and 12 (or early termination)

  6. Percent Predicted FEV1: Mean Change From Baseline

    Percent predicted FEV1: measured FEV1 as a percent of the "predicted values" for the patients of similar characteristics (height, age, sex, and sometimes race and weight). Best FEV1 percent predicted was measured at Visit 1 (screening), pre-dose at baseline, months 3, 6, 9 and 12/EOS, as described for FEV1.

    Time frame: Baseline and on treatments at months 3, 6, 9 and 12 (or early termination)

  7. Forced Vital Capacity (FVC): Mean Change From Baseline

    Forced Vital capacity: the volume of air that can forcibly be blown out after full inspiration. Best FVC was measured at Visit 1 (screening), pre-dose at baseline, months 3, 6, 9 and 12/EOS. The best FVC from at least 3 acceptable maneuvers was recorded.

    Time frame: Baseline and on treatment at months 3, 6, 9 and 12 (or early termination)

  8. Inspiratory Capacity (IC): Mean Change From Baseline

    IC: the total amount of air that can be drawn into the lungs after normal expiration. IC was measured pre- and post-albuterol administration at Visit 1 (screening), pre-dose at baseline, months 3, 6, 9 and 12/EOS. IC maneuvers were done in triplicate. The mean of all recorded IC values was used for each subject at each time point. Study baseline was defined as the Visit 2 pre-dose value. If the Visit 2 pre-dose value was missing, the last IC value obtained prior to first treatment dose was used for baseline.

    Time frame: Baseline and on treatment at months 3, 6, 9 and 12 (or early termination)

07

Results

Posted Nov 11, 2013
Limitations and caveats
Although LABAs other than study medication were discontinued, other medications were not controlled for. A large number of subjects discontinued after a primary event and their eventual outcomes are unknown.

Participant flow

Participant flow — Overall Study
MilestonePlacebo Twice DailyArformoterol 15 Mcg Twice Daily
Started421420
Completed211255
Not completed210165
Withdrew: Adverse event5355
Withdrew: Lack of efficacy74
Withdrew: Lost to follow-up1915
Withdrew: Physician decision82
Withdrew: Protocol violation25
Withdrew: Withdrawal by subject11680
Withdrew: Site ceasing operation22
Withdrew: Medical monitor decision10
Withdrew: Noncompliance11
Withdrew: Randomized in error11

Outcome measures

PrimaryTime From Randomization to Respiratory Death or First COPD Exacerbation Related Hospitalization (Whichever Occurs First).

COPD exacerbation: an increase in COPD symptoms that necessitated any change in baseline medication (bronchodilators,anti-inflammatory agents, antibiotics, supplemental oxygen therapy, etc.).Hospitalization: any inpatient admission or any emergency department visit \> 24 hours in duration. Hospice was considered hospitalization.COPD exacerbation related hospitalization: hospitalization that was due to 1) COPD exacerbation or 2) a COPD exacerbation preceded, or occurred concomitantly with the onset of, the event for which the subject was hospitalized.Respiratory-related death: For each death the Primary Investigator designated a 'probable cause', which was the primary condition that precipitated the terminal events that were the immediate cause of death. If a probable cause could not be ascertained, the cause of death was considered 'UNKNOWN'. Cause other than 'UNKNOWN' was categorized as either respiratory or non-respiratory. Deaths of 'UNKNOWN' cause were counted as primary events.

Time frame:
0-12 months
Reported as:
Mean · Days
Time From Randomization to Respiratory Death or First COPD Exacerbation Related Hospitalization (Whichever Occurs First).
DaysExperimental: Arformoterol 15 Mcg Twice DailyPlacebo
Time From Randomization to Respiratory Death or First COPD Exacerbation Related Hospitalization (Whichever Occurs First).155.0 ± 91.2171.7 ± 98.7
Statistical analysis
  • Experimental: Arformoterol 15 Mcg Twice Daily · Regression, Cox · Hazard ratio (hr): 0.606 · 95% CI 0.425 to 0.864Hazard ratio was calculated as arformoterol vs. placebo.
SecondaryThe Incidence of Protocol Defined COPD Exacerbations.

A protocol-defined exacerbation of COPD was defined as an increase in respiratory symptoms (classically, increased shortness of breath, increased sputum production, and/or increased sputum purulence) that necessitates any change in baseline medication other than bronchodilators (e.g., anti-inflammatory agents, antibiotics, supplemental oxygen therapy, etc) or causes the subject to require additional medical attention (i.e., emergency room visit or hospitalization).

Time frame:
0-12 months
Reported as:
Number · participants
The Incidence of Protocol Defined COPD Exacerbations.
participantsPlacebo Comparator: Placebo Twice DailyExperimental: Arformoterol 15 Mcg Twice Daily
Overall132122
1 COPD event7271
2 COPD events3429
3 or more COPD events2622
SecondaryThe Incidence of All Cause Mortality

Survival status at the end of the study will be determined for each subject. The proportion of subjects dead and the annual event rate will be summarized by treatment.

Time frame:
0-12 months
Reported as:
Number · participants
The Incidence of All Cause Mortality
participantsPlacebo Comparator: Placebo Twice DailyExperimental: Arformoterol 15 Mcg Twice Daily
The Incidence of All Cause Mortality1012
SecondaryThe Incidence of Treatment Emergent AEs

TEAEs were defined as: 1) adverse events that occurred on or after the date of first dose of study medication, 2) adverse events with a missing start date and a stop date on or after the date of first does of study medication, or 3) adverse events with both a missing start and stop date. The frequency and percentage of subjects with TEAEs were summarized. At each level of summarization, a subject was counted only once for each AE he/she experienced within that level. The percentage of subjects having had at least 1 AE at each level was calculated.

Time frame:
0-12 months
Reported as:
Number · participants
The Incidence of Treatment Emergent AEs
participantsPlacebo Comparator: Placebo Twice DailyExperimental: Arformoterol 15 Mcg Twice Daily
The Incidence of Treatment Emergent AEs287306
SecondarySGRQ: Mean Change From Baseline in Total Score

The SGRQ assessed health status and consisted of 3 component scores (Symptoms, Activity, and Impacts) as well as a total score. Items were scored in accordance with the developer's guidelines. Scores were expressed as a percentage of overall impairment, where 100 represented worst possible health status and 0 indicated best possible health status. The SGRQ was assessed pre-dose at baseline, months 3, 6 and 12 or the end of study (EOS). Visit 2 was defined as baseline. A change from baseline in the Total Score of ≥ 4 units is considered the minimal clinically important difference (MCID) for SGRQ.

Time frame:
Baseline and on treatment at months 3, 6 and 12 (or early termination)
Reported as:
Least squares mean · Score
SGRQ: Mean Change From Baseline in Total Score
ScorePlacebo Comparator: Placebo Twice DailyExperimental: Arformoterol 15 Mcg Twice Daily
Month 3 (n=276,308)-1.544 ± 0.609-3.876 ± 0.575
Month 6 (n=233,287)-1.855 ± 0.746-4.054 ± 0.679
Month 12 (n=199,236)-2.673 ± 0.800-4.796 ± 0.735
EOS (n=375,379)-0.587 ± 0.616-3.231 ± 0.613
SecondaryFEV1: Mean Change From Baseline

FEV1 was measured at Visit 1 (screening), pre- and post-albuterol administration for reversibility testing, pre-dose at baseline, months 3, 6, 9 and 12/EOS. The best FEV1 from at least 3 acceptable maneuvers was recorded. Study baseline was defined as the Visit 2 pre-dose value. If the Visit 2 pre-dose value was missing, the last FEV1 value obtained prior to first treatment was used for baseline.

Time frame:
Baseline and on treatments at months 3, 6, 9 and 12 (or early termination)
Reported as:
Mean · Liter
FEV1: Mean Change From Baseline
LiterPlacebo Comparator: Placebo Twice DailyExperimental: Arformoterol 15 Mcg Twice Daily
Month 3 (n=289,331)0.027 ± 0.0180.093 ± 0.016
Month 6 (n=248,300)0.036 ± 0.0230.090 ± 0.021
Month 9 (n=223,268)0.048 ± 0.0190.092 ± 0.018
Month 12 (n=206,253)0.020 ± 0.0200.059 ± 0.018
EOS (n=380,391)0.047 ± 0.0160.072 ± 0.016
SecondaryPercent Predicted FEV1: Mean Change From Baseline

Percent predicted FEV1: measured FEV1 as a percent of the "predicted values" for the patients of similar characteristics (height, age, sex, and sometimes race and weight). Best FEV1 percent predicted was measured at Visit 1 (screening), pre-dose at baseline, months 3, 6, 9 and 12/EOS, as described for FEV1.

Time frame:
Baseline and on treatments at months 3, 6, 9 and 12 (or early termination)
Reported as:
Least squares mean · Liter
Percent Predicted FEV1: Mean Change From Baseline
LiterPlacebo Comparator: Placebo Twice DailyExperimental: Arformoterol 15 Mcg Twice Daily
Month 3 (n=289,331)1.410 ± 0.5333.480 ± 0.498
Month 6 (n=248,300)1.768 ± 0.6483.460 ± 0.594
Month 9 (n=223,268)2.606 ± 0.6263.651 ± 0.576
Month 12 (n=206,252)1.678 ± 0.6422.662 ± 0.586
EOS (n=380,391)2.156 ± 0.4932.936 ± 0.486
SecondaryForced Vital Capacity (FVC): Mean Change From Baseline

Forced Vital capacity: the volume of air that can forcibly be blown out after full inspiration. Best FVC was measured at Visit 1 (screening), pre-dose at baseline, months 3, 6, 9 and 12/EOS. The best FVC from at least 3 acceptable maneuvers was recorded.

Time frame:
Baseline and on treatment at months 3, 6, 9 and 12 (or early termination)
Reported as:
Least squares mean · Liter
Forced Vital Capacity (FVC): Mean Change From Baseline
LiterPlacebo Comparator: Placebo Twice DailyExperimental: Arformoterol 15 Mcg Twice Daily
Month 3 (n=289,331)0.039 ± 0.0240.139 ± 0.022
Month 6 (n=248,300)0.056 ± 0.0310.120 ± 0.028
Month 9 (n=223,268)0.049 ± 0.0290.139 ± 0.027
Month 12 (n=206,253)0.040 ± 0.0290.088 ± 0.027
EOS (n=380,391)0.056 ± 0.0220.102 ± 0.022
SecondaryInspiratory Capacity (IC): Mean Change From Baseline

IC: the total amount of air that can be drawn into the lungs after normal expiration. IC was measured pre- and post-albuterol administration at Visit 1 (screening), pre-dose at baseline, months 3, 6, 9 and 12/EOS. IC maneuvers were done in triplicate. The mean of all recorded IC values was used for each subject at each time point. Study baseline was defined as the Visit 2 pre-dose value. If the Visit 2 pre-dose value was missing, the last IC value obtained prior to first treatment dose was used for baseline.

Time frame:
Baseline and on treatment at months 3, 6, 9 and 12 (or early termination)
Reported as:
Least squares mean · Liter
Inspiratory Capacity (IC): Mean Change From Baseline
LiterPlacebo Comparator: Placebo Twice DailyExperimental: Arformoterol 15 Mcg Twice Daily
Month 3 (n=284,320)0.030 ± 0.0230.054 ± 0.021
Month 6 (n=243,298)-0.011 ± 0.0260.067 ± 0.024
Month 9 (n=218,258)0.046 ± 0.0290.096 ± 0.027
Month 12 (n=199,246)0.004 ± 0.0290.035 ± 0.027
EOS (n=374,384)0.031 ± 0.0220.058 ± 0.021

Adverse events

Collected over 1 year. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Comparator: Placebo Twice Daily—95/421 (22.6%)180/421 (42.8%)
Experimental: Arformoterol 15 Mcg Twice Daily—86/420 (20.5%)174/420 (41.4%)
Most frequent serious events
Showing 10 of 133
Most frequent serious events
EventPlacebo Comparator: Placebo Twice DailyExperimental: Arformoterol 15 Mcg Twice Daily
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders55/42135/420
PneumoniaInfections and infestations14/42112/420
BronchitisInfections and infestations9/4213/420
Acute respiratory failureRespiratory, thoracic and mediastinal disorders4/4211/420
Angina pectorisCardiac disorders1/4213/420
Atrial fibrillationCardiac disorders2/4213/420
Coronary artery diseaseCardiac disorders0/4213/420
Non-cardiac chest painGeneral disorders1/4213/420
SepsisInfections and infestations0/4213/420
Cardiac failure congestiveCardiac disorders3/4212/420
Most frequent other events
Most frequent other events
EventPlacebo Comparator: Placebo Twice DailyExperimental: Arformoterol 15 Mcg Twice Daily
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders83/42175/420
BronchitisInfections and infestations28/42143/420
NasopharyngitisInfections and infestations33/42138/420
HeadacheNervous system disorders21/42135/420
DyspnoeaRespiratory, thoracic and mediastinal disorders30/42124/420
Upper respiratory tract infectionInfections and infestations22/42122/420
SinusitisInfections and infestations22/42119/420

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Placebo Comparator: Placebo Twice DailyExperimental: Arformoterol 15 Mcg Twice DailyTotal
<=18 years000
Between 18 and 65 years222204426
>=65 years199216415
Age Continuous
Age Continuous(years)Placebo Comparator: Placebo Twice DailyExperimental: Arformoterol 15 Mcg Twice DailyTotal
Mean63.3 ± 9.564.2 ± 9.363.8 ± 9.4
Sex/Gender, Customized
Sex/Gender, Customized(participants)Placebo Comparator: Placebo Twice DailyExperimental: Arformoterol 15 Mcg Twice DailyTotal
Female178183361
Male243236479
Undifferentiated011
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo Comparator: Placebo Twice DailyExperimental: Arformoterol 15 Mcg Twice DailyTotal
Hispanic or Latino15924
Not Hispanic or Latino402411813
Unknown or Not Reported404
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo Comparator: Placebo Twice DailyExperimental: Arformoterol 15 Mcg Twice DailyTotal
American Indian or Alaska Native112
Asian224
Native Hawaiian or Other Pacific Islander000
Black or African American434588
White374372746
More than one race000
Unknown or Not Reported101
Region of Enrollment
Region of Enrollment(participants)Placebo Comparator: Placebo Twice DailyExperimental: Arformoterol 15 Mcg Twice DailyTotal
United States421420841
Number of COPD exacerbations in last year
Number of COPD exacerbations in last year(Number of occurrences)Placebo Comparator: Placebo Twice DailyExperimental: Arformoterol 15 Mcg Twice DailyTotal
Mean0.8 ± 1.11.0 ± 1.40.9 ± 1.3
FEV1
FEV1(Liter)Placebo Comparator: Placebo Twice DailyExperimental: Arformoterol 15 Mcg Twice DailyTotal
Mean1.178 ± 0.4871.176 ± 0.4821.177 ± 0.485

5 further baseline measures are reported on the registry.

08

Study locations

73 sites
  • Jefferson Clinic
    Birmingham, Alabama 25233, United States
  • Alabama Clinical Therapeutic, LLC
    Birmingham, Alabama 35235, United States
  • Achieve Clinical Research
    Brimingham, Alabama 35209, United States
  • Jasper Summit Research, LLC
    Jasper, Alabama 35501, United States
  • Chest Critical Care Consultants
    Anaheim, California 92801, United States
  • California Research Medical Group
    Fullerton, California 92835, United States
  • Integrated Research Group
    Riverside, California 92506, United States
  • Quality Control Research Inc.
    Roseville, California 95661, United States
  • Sockolov and Sockolov APC
    Sacramento, California 95825, United States
  • Centers for Clinical Trials of Sacremento
    Sacremento, California 95823, United States
  • Institute of HealthCare Assessment, Inc.
    San Diego, California 92120, United States
  • National Jewish Health
    Denver, Colorado 80206, United States
  • Southeast Clinical Research
    Chiefland, Florida 32626, United States
  • Tampa Bay Medical Research Inc.
    Clearwater, Florida 33761, United States
  • Clinical Research of West Florida, Inc.
    Clearwater, Florida 33765, United States
  • Avail Clinical Research
    DeLand, Florida 32720, United States
  • The Lung Clinic, P.A.
    Kissimmee, Florida 34741, United States
  • DCT
    Orlando, Florida 32806, United States
  • Clinical Research of West Florida
    Tampa, Florida 33603, United States
  • Canton, Georgia 30114, United States
  • Southeast Regional Research Group
    Columbus, Georgia 31904, United States
  • Atlanta Pharmaceutical Research
    Decatur, Georgia 30033, United States
  • Wellstar Marietta Pulmonary Medicine
    Marietta, Georgia 30060, United States
  • Southeast Regional Research Group
    Rincon, Georgia 31326, United States
  • Medisphere Medical Research Center
    Evansville, Indiana 47714, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • Kentucky Lung Clinic
    Hazard, Kentucky 41701, United States
  • Bendel Medical Research Center, LLC
    Lafayette, Louisiana 70503, United States
  • ClinSite LLC
    Ann Arbor, Michigan 48106, United States
  • Clinical Research Institute Inc.
    Minneapolis, Minnesota 55402, United States
  • Midwest Chest Consultants
    St. Charles, Missouri 63301, United States
  • C.A.R.E. Clinical Research
    St. Louis, Missouri 63141, United States
  • Comprehensive Clinical Research
    Berlin, New Jersey 08009, United States
  • Delaware Valley Clinical Research
    Cherry Hill, New Jersey 08003, United States
  • New York Pulmonary and Clinical Care Associates, PC
    New York, New York 10016, United States
  • ENT & Allergy Associates
    Newburgh, New York 12550, United States
  • Rochester Clinical Research
    Rochester, New York 14609, United States
  • AAIR Research Center
    Rochester, New York 14618, United States
  • American Health Research Inc.
    Charlotte, North Carolina 28207, United States
  • Piedmont Medical Research
    Winston-Salem, North Carolina 27103, United States
  • DayStar Clinical Research, Inc.
    Akron, Ohio 44313, United States
  • Bernstein Clinical Research Center
    Cincinnati, Ohio 45231, United States
  • Clinical Research Institute of Southern Oregon, PC
    Medford, Oregon 97504, United States
  • Allergy Associates Research Center
    Portland, Oregon 97216, United States
  • Arcuri Clinical Research, LLC
    Philadelphia, Pennsylvania 19142, United States
  • Biomedical Research Alliance at Hypertension and Nephrology
    Pawtucket, Rhode Island 02860, United States
  • Omega Medical Research
    Warwick, Rhode Island 02886, United States
  • Lowcountry Lung & Critical Care, PA
    Charleston, South Carolina 29406, United States
  • Neem Research Group, Inc.
    Columbia, South Carolina 29201, United States
  • Gaffney Pharmaceutical Research
    Gaffney, South Carolina 29340, United States
  • Greenville Pharmaceutical Research
    Greenville, South Carolina 29615, United States
  • Upstate Pharmaceutical Research
    Greenville, South Carolina 29615, United States
  • Mountain View Clinical Research, Inc.
    Greer, South Carolina 29651, United States
  • S. Carolina Pharmaceutical Research
    Spartanburg, South Carolina 29303, United States
  • CU Pharmaceutical Research
    Union, South Carolina 29379, United States
  • Allergy Associates
    Knoxville, Tennessee 37909, United States
  • Volunteer Research Group
    Knoxville, Tennessee 37920, United States
  • DCT
    Arlington, Texas 76014, United States
  • Baylor College of Medicine, Clinical Studies Unit, Ben Taub General Hospital
    Houston, Texas 77030, United States
  • VAMC
    Houston, Texas 77030, United States
  • Kingwood Research Institute, LLC
    Kingwood, Texas 77339, United States
  • Physician PrimeCare Research
    San Antonio, Texas 78212, United States
  • Diagnostics Research Group
    San Antonio, Texas 78229, United States
  • DCT
    Sugar Land, Texas 77878, United States
  • SouthEast Research Institute
    Webster, Texas 77598, United States
  • National Clinical Resources, Inc.
    Provo, Utah 84604, United States
  • Utah Clinical Trials LLC
    Salt Lake City, Utah 84107, United States
  • Charlottesville Medical Research Inc.
    Charlottesville, Virginia 22911, United States
  • Manassas Clinical Research Center
    Manassas, Virginia 20110, United States
  • Dominion Medical Associates
    Richmond, Virginia 23219, United States
  • Pulmonary Associates of Richmond Inc.
    Richmond, Virginia 23225, United States
  • Pulmonary Associates of Richmond, Inc.
    Richmond, Virginia 23229, United States
  • Pulmonary Consultants, PLLC
    Tacoma, Washington 98405, United States
09

References and documents

Publications

  • Donohue JF, Ganapathy V, Bollu V, Stensland MD, Nelson LM. Health Status of Patients with Moderate to Severe COPD after Treatment with Nebulized Arformoterol Tartrate or Placebo for 1 Year. Clin Ther. 2017 Jan;39(1):66-74. doi: 10.1016/j.clinthera.2016.11.021. Epub 2016 Dec 20. PubMed 28011247 ↗
  • Donohue JF, Hanania NA, Make B, Miles MC, Mahler DA, Curry L, Tosiello R, Wheeler A, Tashkin DP. One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD. Chest. 2014 Dec;146(6):1531-1542. doi: 10.1378/chest.14-0117. PubMed 25451347 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2009, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2013, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2009
First posted
May 28, 2009
Start
Jun 2009
Primary completionActual
Jun 2012
CompletionActual
Jun 2012
Results first posted
Nov 11, 2013
Last update
Nov 11, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 11, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00909779
Responsible party
Sponsor
First posted
May 28, 2009
Start date
Jun 2009
Primary completion
Jun 2012
Completion
Jun 2012
Results posted
Nov 11, 2013
Last update
Nov 11, 2013

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Formoterol

Start the discussion